CANGRELOR IN ELDERLY PATIENTS UNDERGOING PCI: FINDINGS FROM CHAMPION-PHOENIX  by Cavender, Matthew et al.
TCT@ACC-i2: Interventional Cardiology
A1773
JACC March 17, 2015
Volume 65, Issue 10S
CanGrelor in elderly patients UnderGoinG pCi: FindinGs From Champion-phoenix
Poster Contributions
Poster Hall B1
Saturday, March 14, 2015, 3:45 p.m.-4:30 p.m.
Session Title: Coronary II
Abstract Category: 28. TCT@ACC-i2: ACS/AMI/Hemodynamics and Pharmacology
Presentation Number: 2101-286
Authors: Matthew Cavender, Deepak Bhatt, Gregg Stone, Philippe Steg, C. Michael Gibson, Christian Hamm, Matthew Price, Jayne Prats, 
Tiepu Liu, Efthymios Deliargyris, Kenneth Mahaffey, Harvey White, Robert Harrington, Brigham and Women’s Hospital, Boston, MA, USA
background:  Elderly patients treated with PCI are at increased risk of periprocedural ischemic and bleeding events. We sought to 
characterize the effects of cangrelor, an intravenous P2Y12 inhibitor that reduces cardiovascular events during PCI, in elderly patients.
methods:  CHAMPION-PHOENIX randomized 11,145 patients undergoing PCI in a double blind, double dummy fashion to either cangrelor 
or a loading dose of clopidogrel. Outcomes in the prespecified subgroup of elderly patients (defined as 75 years) are reported (n=2010, 
19%).
results:  Treatment with cangrelor resulted in directionally consistent effects on the primary endpoint of death, MI, ischemia driven 
revascularization (IDR), or stent thrombosis (ST) in patients 75 years old (OR 0.71, 95%CI 0.50-1.02) and in those <75 years old (OR 
0.81, 95%CI 0.67-0.98) (p-int=0.55, Figure). GUSTO severe bleeding was uncommon in elderly patients and there was no difference with 
cangrelor or clopidogrel (0.3% vs. 0.5%; OR 0.58, 95%CI 0.14-2.44). For the net composite endpoint of death, MI, IDR, ST or GUSTO 
severe bleeding, the OR for cangrelor in the elderly was 0.71 (5.7% vs 7.8%, 95%CI 0.50-1.01, p=0.06).
Conclusion:  Compared with clopidogrel, cangrelor provides similar net clinical benefit in elderly patients as in non-elderly patients. There 
does not appear to be an appreciable excess bleeding hazard in the elderly when compared to non-elderly patients receiving cangrelor in 
this trial.
 
